Metropolitan Life Insurance CO Apellis Pharmaceuticals, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

50 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $32,473 - $46,671	-697 Reduced 12.09%	5,066 $334,000
Q4 2022 Jun 14, 2023	BUY	$43.24 - $61.04 $30,138 - $42,544	697 Added 13.76%	5,763 $298 Million
Q4 2022 Mar 30, 2023	BUY	$43.24 - $61.04 $5,664 - $7,996	131 Added 2.33%	5,763 $298,000
Q4 2022 Feb 15, 2023	BUY	$43.24 - $61.04 $5,664 - $7,996	131 Added 2.33%	5,763 $298,000
Q3 2022 Jun 14, 2023	BUY	$44.76 - $69.66 $25,334 - $39,427	566 Added 11.17%	5,632 $385 Million
Q3 2022 Mar 30, 2023	BUY	$44.76 - $69.66 $6,714 - $10,449	150 Added 2.74%	5,632 $384,000
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $6,714 - $10,449	150 Added 2.74%	5,632 $385,000
Q2 2022 Jun 20, 2023	BUY	$35.07 - $59.21 $14,589 - $24,631	416 Added 8.21%	5,482 $247,000
Q2 2022 Mar 30, 2023	BUY	$35.07 - $59.21 $20,621 - $34,815	588 Added 12.01%	5,482 $247,000
Q2 2022 Aug 11, 2022	BUY	$35.07 - $59.21 $20,621 - $34,815	588 Added 12.01%	5,482 $248,000
Q1 2022 Jun 20, 2023	SELL	$35.46 - $54.12 $6,099 - $9,308	-172 Reduced 3.4%	4,894 $248,000
Q1 2022 Mar 30, 2023	SELL	$35.46 - $54.12 $479,135 - $731,269	-13,512 Reduced 73.41%	4,894 $248,000
Q1 2022 May 12, 2022	SELL	$35.46 - $54.12 $479,135 - $731,269	-13,512 Reduced 73.41%	4,894 $249,000
Q4 2021 Jun 21, 2023	BUY	$30.74 - $49.16 $410,071 - $655,794	13,340 Added 263.32%	18,406 $870,000
Q4 2021 Mar 30, 2023	BUY	$30.74 - $49.16 $23,024 - $36,820	749 Added 4.24%	18,406 $870,000
Q4 2021 Feb 15, 2022	BUY	$30.74 - $49.16 $23,024 - $36,820	749 Added 4.24%	18,406 $870,000
Q3 2021 Jun 21, 2023	BUY	$31.4 - $69.84 $395,357 - $879,355	12,591 Added 248.54%	17,657 $581,000
Q3 2021 Mar 30, 2023	BUY	$31.4 - $69.84 $9,137 - $20,323	291 Added 1.68%	17,657 $581,000
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $9,137 - $20,323	291 Added 1.68%	17,657 $582,000
Q2 2021 Jun 21, 2023	BUY	$40.9 - $64.9 $503,070 - $798,270	12,300 Added 242.8%	17,366 $1.1 Million
Q2 2021 Mar 30, 2023	BUY	$40.9 - $64.9 $43,885 - $69,637	1,073 Added 6.59%	17,366 $1.1 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $709,615 - $1.13 Million	17,350 Added 108437.5%	17,366 $1.1 Million
Q1 2021 Jun 26, 2023	BUY	$40.8 - $57.39 $458,061 - $644,317	11,227 Added 221.61%	16,293 $699 Million
Q1 2021 Mar 30, 2023	SELL	$40.8 - $57.39 $35,088 - $49,355	-860 Reduced 5.01%	16,293 $699,000
Q1 2021 May 14, 2021	SELL	$40.8 - $57.39 $699,189 - $983,492	-17,137 Reduced 99.91%	16 $699,000
Q4 2020 Jun 22, 2023	BUY	$30.79 - $57.2 $372,158 - $691,376	12,087 Added 238.59%	17,153 $981,000
Q4 2020 Mar 30, 2023	SELL	$30.79 - $57.2 $36,547 - $67,896	-1,187 Reduced 6.47%	17,153 $981,000
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $36,547 - $67,896	-1,187 Reduced 6.47%	17,153 $981,000
Q3 2020 Jun 26, 2023	BUY	$25.89 - $33.65 $343,663 - $446,670	13,274 Added 262.02%	18,340 $553,000
Q2 2020 Jun 26, 2023	BUY	$24.8 - $38.49 $329,195 - $510,916	13,274 Added 262.02%	18,340 $598,000
Q2 2020 Mar 30, 2023	BUY	$24.8 - $38.49 $8,853 - $13,740	357 Added 1.99%	18,340 $598,000
Q2 2020 Aug 14, 2020	BUY	$24.8 - $38.49 $8,853 - $13,740	357 Added 1.99%	18,340 $599,000
Q1 2020 Jul 12, 2023	BUY	$17.91 - $44.33 $235,337 - $582,496	13,140 Added 259.38%	18,206 $487,000
Q1 2020 Mar 30, 2023	BUY	$17.91 - $44.33 $33,187 - $82,143	1,853 Added 11.49%	17,983 $481,000
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $33,187 - $82,143	1,853 Added 11.49%	17,983 $482,000
Q4 2019 Jul 12, 2023	BUY	$22.1 - $30.8 $244,514 - $340,771	11,064 Added 218.4%	16,130 $493,000
Q3 2019 Jul 12, 2023	BUY	$24.09 - $32.18 $266,531 - $356,039	11,064 Added 218.4%	16,130 $388,000
Q3 2019 Mar 30, 2023	BUY	$24.09 - $32.18 $94,288 - $125,952	3,914 Added 32.04%	16,130 $388,000
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $94,288 - $125,952	3,914 Added 32.04%	16,130 $389,000
Q2 2019 Jul 12, 2023	BUY	$18.0 - $25.34 $143,874 - $202,542	7,993 Added 157.78%	13,059 $330,000
Q1 2019 Jul 13, 2023	BUY	$12.81 - $19.82 $91,591 - $141,713	7,150 Added 141.14%	12,216 $238,000
Q1 2019 Mar 30, 2023	BUY	$12.81 - $19.82 $82,662 - $127,898	6,453 Added 111.97%	12,216 $238,000
Q1 2019 May 16, 2019	BUY	$12.81 - $19.82 $46,730 - $72,303	3,648 Added 42.58%	12,216 $238,000
Q1 2019 May 15, 2019	SELL	$12.81 - $19.82 $46,730 - $72,303	-3,648 Reduced 29.86%	8,568 $291,000
Q4 2018 Jul 13, 2023	BUY	$11.47 - $18.71 $82,010 - $133,776	7,150 Added 141.14%	12,216 $161,000
Q4 2018 Feb 14, 2019	BUY	$11.47 - $18.71 $109,435 - $178,512	9,541 Added 356.67%	12,216 $161,000
Q3 2018 Jul 13, 2023	BUY	$16.57 - $21.03 $118,475 - $150,364	7,150 Added 141.14%	12,216 $217 Million
Q3 2018 Nov 14, 2018	BUY	$16.57 - $21.03 $44,324 - $56,255	2,675 New	2,675 $48,000
Q2 2018 Aug 15, 2018	SELL	$19.63 - $30.0 $78,912 - $120,600	-4,020 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$14.01 - $26.02 $56,320 - $104,600	4,020 New	4,020 $0

Others Institutions Holding APLS

# of Institutions

310

Shares Held

113M

Call Options Held

3.85M

Put Options Held

1.09M

Wellington Management Group LLP Boston, MA

15.6M
Shares

$473 Million
0.08% of portfolio
Eco R1 Capital, LLC San Francisco, CA

11.9M
Shares

$361 Million
14.88% of portfolio
Avoro Capital Advisors LLC New York, NY

11.1M
Shares

$338 Million
4.82% of portfolio
Vanguard Group Inc Valley Forge, PA

9.82M
Shares

$298 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.8M
Shares

$176 Million
0.01% of portfolio

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.34B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account